ARCA Biotechnology Competition

Summary

BTK Index

5,688 30.71 0.54%

ARCA Biotechnology competes with SEI Investments, Fidus Investment, Morgan Stanley, Freedom Holding, and Small Cap; as well as few others. Analyzing ARCA Biotechnology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ARCA Biotechnology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any index could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of ARCA Biotechnology competition on your existing holdings.

Specify up to 10 symbols:

ARCA Biotechnology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ARCA Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding indexs. A correlation of about +1.0 implies that the price of ARCA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ARCA Biotechnology does not affect the price movement of the other competitor.

	SEIC	FDUS	MS	FRHC	RCC	EQIX	MNTK
SEIC		0.87	0.91	0.96	0.74	0.88	-0.68	SEIC
FDUS	0.87		0.76	0.88	0.58	0.91	-0.87	FDUS
MS	0.91	0.76		0.83	0.72	0.73	-0.52	MS
FRHC	0.96	0.88	0.83		0.75	0.87	-0.74	FRHC
RCC	0.74	0.58	0.72	0.75		0.59	-0.47	RCC
EQIX	0.88	0.91	0.73	0.87	0.59		-0.72	EQIX
MNTK	-0.68	-0.87	-0.52	-0.74	-0.47	-0.72		MNTK
	SEIC	FDUS	MS	FRHC	RCC	EQIX	MNTK

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

FRHC	+ 0.96	SEIC
MS	+ 0.91	SEIC
EQIX	+ 0.91	FDUS
EQIX	+ 0.88	SEIC
FRHC	+ 0.88	FDUS
FDUS	+ 0.87	SEIC

High negative correlations

MNTK	- 0.87	FDUS
MNTK	- 0.74	FRHC
MNTK	- 0.72	EQIX
MNTK	- 0.68	SEIC
MNTK	- 0.52	MS
MNTK	- 0.47	RCC

Risk-Adjusted Indicators

There is a big difference between ARCA Index performing well and ARCA Biotechnology Index doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ARCA Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
SEIC	0.89	0.25	0.18	0.26	1.09	(1.00)	1.57	(1.58)	10.37
FDUS	0.57	0.06	0.05	0.15	0.66	(0.59)	1.18	(1.32)	4.32
MS	1.24	0.27	0.22	0.16	0.98	(1.59)	3.08	(1.93)	16.86
FRHC	1.35	0.42	0.22	0.66	1.34	(1.42)	3.26	(2.40)	9.39
RCC	0.36	0.05	0.06	17.35	0.28	(0.51)	1.03	(0.70)	2.37
EQIX	0.86	0.10	0.07	0.42	1.15	(0.84)	1.49	(1.70)	7.64
MNTK	2.68	(0.36)	0.00	(0.23)	0.00	0.00	4.73	(4.81)	25.54

Unable to evaluate fundamental data of ARCA Biotechnology at this time. Please try again later

All Fundamental Data

ARCA Biotechnology Competitive Analysis

The better you understand ARCA Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ARCA Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ARCA Biotechnology's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	BTK	SEIC	FDUS	MS	FRHC	RCC	EQIX	MNTK
	0.54 5,688 ARCA	0.88 81.47 SEI	1.81 20.28 Fidus	0.45 120.50 Morgan	0.85 127.20 Freedom	1.63 25.00 Small	0.52 921.57 Equinix	1.60 3.69 Montauk
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Moderately volatile
Market Performance (90 Days Performance)	Very Weak	Solid	Good	Good	Solid	Insignificant	Modest	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Unknown	Low	Very Low	Very Low	Low	Very Low	Very Small	Very Low
Current Valuation (Equity Enterprise Value)	Over Valued	Fairly Valued	Fairly Valued	Over Valued	Over Valued	Fairly Valued	Over Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Buy	Buy	Buy	Strong Sell	Strong Sell	Strong Buy	Hold
Trade Advice (90 Days Macroaxis Advice)	Cautious Hold	Strong Buy	Strong Buy	Strong Hold	Strong Buy	Strong Hold	Strong Hold	Hold
Current Ratio		4.43 X	2.58 X	2.00 X	1.18 X	N/A	2.37 X	3.43 X
Net Asset		2.52 B	1.09 T	1.19 T	8.3 B	12.44 B	32.65 B	350.24 M
Profit Margin		0.27 %	0.60 %	0.19 %	0.26 %	N/A	0.13 %	0.12 %
EBITDA		424.52 M	102.6 M	23.55 B	865.11 M	899.56 M	2.01 B	45.28 M
Operating Margin		0.27 %	0.73 %	0.33 %	0.27 %	N/A	0.16 %	0.35 %
Current Valuation		9.51 B	1.09 B	55.87 B	6.07 B	N/A	105.35 B	546.83 M
Price To Book		4.42 X	1.04 X	2.08 X	6.06 X	N/A	6.54 X	1.96 X
Retained Earnings		762.59 M	85.14 M	98 B	998.74 M	124.41 M	(4.76 B)	45.61 M
Current Asset		1 B	N/A	N/A	N/A	N/A	63.49 M	N/A
Five Year Return		1.18 %	10.25 %	2.52 %	N/A	N/A	1.74 %	N/A
Beta		0.97	1.44	1.34	1.02	N/A	0.7	-0.21
Number Of Employees		5.06 K	N/A	80 K	7.15 K	6	13.15 K	151
Shares Outstanding		128.91 M	33.91 M	1.61 B	60.61 M	N/A	96.49 M	143.37 M
Cash Flow From Operations		447.03 M	48.41 M	(33.54 B)	(1.06 B)	54.06 M	3.34 B	41.05 M
Annual Yield		0.01 %	0.12 %	0.03 %	N/A	0.03 %	0.02 %	N/A
Total Debt		25.35 M	204.47 B	276.39 B	3.07 B	7.24 B	17.46 B	68.09 M
Return On Equity		0.25	0.14	0.11	0.31	0.14	0.0827	0.0886
Return On Asset		0.13	0.0565	0.0094	0.0427	N/A	0.0256	0.0607
Number Of Shares Shorted		1.34 M	174.78 K	15.33 M	352.98 K	N/A	1.65 M	1.58 M
Book Value Per Share		18.29 X	19.42 X	58.25 X	20.81 X	N/A	140.83 X	1.94 X
Current Liabilities		224.48 M	N/A	N/A	N/A	N/A	46.17 M	N/A
Total Asset		2.52 B	1.09 T	1.19 T	8.3 B	12.44 B	32.65 B	350.24 M
Debt To Equity		0.01 %	0.80 %	3.42 %	1.69 %	N/A	1.44 %	0.37 %
Short Ratio		2.07 X	0.79 X	2.24 X	3.65 X	N/A	2.87 X	6.77 X
Target Price		78.8	21.0	126.67	76.0	N/A	1003.0	5.94
Last Dividend Paid		0.92	1.72	3.55	N/A	N/A	17.04	N/A
Shares Owned By Institutions		73.00 %	24.10 %	62.10 %	1.01 %	N/A	98.50 %	16.83 %
Market Capitalization		10.5 B	687.79 M	194.13 B	7.65 B	1.74 B	88.92 B	537.63 M
Price To Earning		19.70 X	15.91 X	13.51 X	16.11 X	N/A	87.82 X	73.25 X
Price To Earnings To Growth		1.25 X	3.59 X	3.50 X	N/A	N/A	5.24 X	N/A
Price To Sales		5.12 X	4.66 X	3.33 X	5.85 X	N/A	10.58 X	2.76 X
Net Income		462.26 M	77.13 M	9.09 B	375.54 M	351.25 M	969.18 M	14.95 M
Earnings Per Share		4.15 X	2.83 X	6.58 X	5.70 X	N/A	11.12 X	0.17 X
Shares Owned By Insiders		23.89 %	1.02 %	23.67 %	70.95 %	N/A	0.27 %	68.14 %
Revenue		1.92 B	154.18 M	53.61 B	1.64 B	1.15 B	8.19 B	174.9 M
Working Capital		1.13 B	N/A	N/A	2.11 B	N/A	405.45 M	60.83 M
Cash And Equivalents		791.44 M	72.47 M	122.72 B	2.15 B	N/A	2.5 B	72.47 M
Cash Per Share		5.87 X	2.96 X	325.70 X	36.11 X	N/A	27.02 X	0.52 X
Gross Profit		1.58 B	94.14 M	46.44 B	468.93 M	N/A	2.97 B	104.13 M
Day Typical Price	5681.4	81.69	20.24	121.91	127.93	24.83	926.98	3.74
Accumulation Distribution	0.0146	9634.47	3066.93	320599.0	1802.94	89.12	13546.55	1457.11
Market Facilitation Index	83.5	0.0	0.0	0.0	1.0E-4	1.0E-4	0.0	0.0
Daily Balance Of Power	(0.37)	0.6893	1.090909	(0.12)	0.3057	0.8	(0.26)	(0.30)
Period Momentum Indicator	(30.71)	0.71	0.36	(0.54)	1.07	0.4	(4.81)	(0.06)
Rate Of Daily Change	0.99	1.01	1.02	1.0	1.01	1.02	0.99	0.98
Day Median Price	5677.97	81.81	20.23	122.62	128.29	24.75	929.68	3.77
Price Action Indicator	(5.07)	0.02	0.24	(2.39)	(0.55)	0.45	(10.51)	(0.11)
Coefficient Of Variation	8399.05	478.62	1023.61	641.31	410.66	798.45	997.58	(1,274)
Mean Deviation	0.8052	0.8866	0.5669	1.24	1.35	0.363	0.8613	2.68
Total Risk Alpha	(0.03)	0.2328	0.0428	0.2547	0.3819	0.0388	0.0726	(0.44)
Jensen Alpha	N/A	0.2485	0.0556	0.2693	0.4204	0.0537	0.1011	(0.36)
Sortino Ratio	(0.01)	0.1766	0.052	0.2208	0.2169	0.064	0.0659	N/A
Downside Variance	1.93	1.99	0.6589	1.76	3.62	0.2251	1.61	N/A
Standard Deviation	1.13	1.35	0.7745	2.09	1.83	0.5092	1.17	4.0
Kurtosis	3.79	5.98	1.46	13.55	0.815	1.24	2.07	10.31
Potential Upside	1.59	1.57	1.18	3.08	3.26	1.03	1.49	4.73
Maximum Drawdown	6.9	10.37	4.32	16.86	9.39	2.37	7.64	25.54
Treynor Ratio	N/A	0.2632	0.1521	0.1574	0.6571	17.35	0.4212	(0.23)
Variance	1.27	1.83	0.5999	4.38	3.35	0.2593	1.36	16.04
Market Risk Adjusted Performance	N/A	0.2732	0.1621	0.1674	0.6671	17.36	0.4312	(0.22)
Risk Adjusted Performance	0.0124	0.17	0.0773	0.13	0.199	0.0939	0.0828	(0.05)
Skewness	(1.18)	(0.02)	0.2188	2.59	0.0023	0.6109	(0.07)	(1.62)
Semi Deviation	1.31	1.09	0.6611	0.9768	1.34	0.2809	1.15	N/A
Information Ratio	(0.02)	0.1842	0.0545	0.14	0.2253	0.0596	0.0716	(0.09)
Value At Risk	(1.45)	(1.58)	(1.32)	(1.93)	(2.40)	(0.70)	(1.70)	(4.81)
Expected Short fall	(0.71)	(1.00)	(0.59)	(1.59)	(1.42)	(0.51)	(0.84)	N/A
Downside Deviation	1.39	1.41	0.8117	1.33	1.9	0.4744	1.27	N/A
Semi Variance	1.71	1.19	0.437	0.9541	1.8	0.0789	1.31	N/A

ARCA Biotechnology Competition Performance Charts

Five steps to successful analysis of ARCA Biotechnology Competition

ARCA Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ARCA Biotechnology in relation to its competition. ARCA Biotechnology's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of ARCA Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ARCA Biotechnology's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ARCA Biotechnology, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ARCA Biotechnology position

In addition to having ARCA Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Printing and Publishing Thematic Idea Now

Printing and Publishing

Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 21 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.

View All Next

Launch

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC